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Abstract 
Background: Methadone is currently the most frequently used substance in the treatment of short-
term and particularly long-term opiate dependence. Patients' beliefs about the adverse effects of 
methadone on function of organs, especially liver, have widely affected the use of this substance. This 
study aimed to determine the effects of methadone on liver enzyme levels in patients on methadone 
maintenance treatment. 
Methods: In a retrospective study, a total of 94 patients undergoing methadone maintenance therapy 
were recruited from Shahid Beheshti Hospital (Kerman, Iran). Liver enzyme levels in all patients were 
tested every six months from the onset of treatment until 24 months. The relations between test 
results and age, gender, and methadone dose were then evaluated. Data was analyzed using logistic 
regression with random data plan. 
Findings: At the 24th month, alanine aminotransferase (ALT) levels in 4 patients (4.3%) and aspartate 
aminotransferase (AST) levels in 3 patients (3.2%) were above normal. Among 46 patients (50.0%) 
who had normal alkaline phosphatase (ALP) levels after 24 months, 26 subjects were younger than 40 
and 20 subjects were over 40 years of age. The mean age of subjects with abnormal ALP levels and the 
mean methadone dose were 39.9 years and 19.55 cc, respectively. 
Conclusion: The results of this study indicated the significant effect of methadone on ALP levels. These 
effects can account for cholestatic pattern liver injury (obstruction). Further prospective studies 
including greater samples of patients with heart and liver complications and encompassing other 
drugs are required to confirm our findings. 
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Introduction  
Opiate abuse and dependence is a complex, 
multidimensional problem. In a survey by the 
Iranian Ministry of Health in 2004, in male 
gender, addiction was the second cause of years 
lost due to disability after accidents.1,2 Injection 
substance abuse is a major public health 
concern with side-effects including human 
immunodeficiency virus (HIV) and hepatitis 
infections. Detoxification or medically managed 
withdrawal programs alone are not considered 
as an effective treatment for dependence to 
opiates including heroin.3 Oral methadone is 
currently recognized as the international 
method for treating heroin dependence. 
Methadone removes or minimizes withdrawal 
symptoms and thus reduces reliance on heroin. 
Methadone is effective for 24 hours and can act 
as a substitute for 3-5 times of heroin 
consumption (short long effect). Moreover, 
methadone blocks the euphoric effects of heroin 
and thereby helps reduce patients' craving. 
Overall, methadone has been recognized as 
the most effective researched substance for the 
treatment of opiate-dependent patients.4 
Methadone is metabolized in the liver by 
cytochrome P450 and its metabolite is secreted 
in urine. Women metabolize methadone more 
rapidly compared to men. Following oral 
administration, methadone has an initial half-
life of 12-24 hours and a secondary half-life of 
55 hours.5,6 
There is a widely held assumption about the 
adverse effects of methadone. However, few 
reports, including two studies in the 1960s on 
only three patients whose history prior to 
methadone treatment was not available, have 
actually confirmed such adverse effects.7,8 In a 
prospective study conducted by Kreek et al. in 
1972, a total of 129 heroin-dependent patients 
on methadone maintenance treatment (using 
80-120 mg of methadone) were evaluated for 
three years. The researchers found no 
substantial evidence to support liver toxicity by 
methadone and postulated that hepatitis and 
alcohol overconsumption may be the possible 
factors leading to liver dysfunction in these 
patients.9 In another study conducted in New 
York, patients consuming high doses of 
methadone following alcohol and barbiturate 
overdoses were tested. In 7% of the subjects, 
increased levels of alkaline phosphatase (ALP) 
were observed but restored to normal after a 
given time.10 In Iran, Tashakori et al. evaluated 
98 addicts (71% heroin-dependent, 7 HIV 
positive subjects) undergoing methadone 
maintenance treatment. They reported liver 
function values to remain normal during the 
year following methadone treatment. In 
hepatitis C virus (HCV) positive patients, 
however, the values elevated shortly after 
treatment and then remained moderate during 
the remainder of the course. The researchers 
thus stated that methadone may be hepatotoxic 
in HCV positive patients and should be used 
with caution in these patients.11 Although very 
few studies have indicated the effects of HCV 
infection on methadone serum levels, a number 
of researchers have suggested methadone to be 
used with monitoring of methadone serum 
levels in HCV positive patients.12  
There are several noninvasive laboratory 
tests to assess liver. Repeated application of 
these tests can detect alteration in liver function 
and evaluate specific patterns of liver 
dysfunction. However, although these tests are 
capable of distinguishing between viral 
hepatitis and cholestatic syndromes, they 
cannot be used as a pathognomonic test for a 
certain liver disease.13 These tests are not highly 
sensitive and may exhibit normal findings in 
patients with severe liver disease. However, in 
evaluating the severity of disease, these tests 
can contribute to other data in predicting 
disease prognosis.14 Alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) 
levels and their ratio are the most frequently 
used tests in liver function assessment. Elevated 
levels of ALT and AST indicate their release 
from tissues rich in these enzymes. Such an 
event may suggest liver cell death. Tissues rich 
in AST include liver, heart, skeletal muscles, 
pancreas, and lungs. ALT is normally found in 
liver and kidneys. High levels of these enzymes 
are nevertheless not necessarily indicative of 
liver damage or necrosis. Elevations of these 
enzymes up to 8 folds of their normal limits are 
non-specific and can be seen in any liver 
disease or specific clinical populations.15 Most 
elevations are observed in hepatocellular 
damage such as alcohol hepatotoxicity and 
viral hepatitis. Since in acute or chronic liver 
conditions, enzyme elevations may not be 
persistent over time, a single test cannot 
determine the degree of liver disease.6 Elevated 
alkaline phosphatase levels may suggest 
cholestasis or liver infiltration.16  
Studies on hepatotoxicity of methadone have 
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been very few and brief. Therefore, given the 
increasing population of patients on methadone 
treatment in Iran, this retrospective study 
aimed to measure AST, ALT, and ALP levels in 
patients on methadone maintenance treatment 
prior and two years following the onset of 
treatment. It also tried to determine alterations 
in the mentioned variables with respect to age, 
gender, and dosage of methadone. 
 
Methods 
In a retrospective study, a total of 94 patients 
undergoing methadone maintenance treatment 
in Shahid Beheshti Hospital (Kerman, Iran) 
were recruited. Written consents were obtained 
from patients to use their hospital records in the 
study. Patient records included demographic 
characteristics, initiation date of methadone 
maintenance treatment, dates of visits, and 
dosage of methadone used. Liver enzyme levels 
including ALT, AST and ALP levels were tested 
at the onset of methadone maintenance 
treatment and every 6 months for a period of 24 
months. The results of the final test were 
registered in patient records.  
Patients were included if they had been on 
methadone maintenance treatment for at least 
one year since this trial also lasted for a year. 
Methadone dosage was determined by the 
clinic's physician based on the amount of opiate 
used by the patient. The main variables were 
defined and enzyme alterations were 
demonstrated using linear graphs. Linear 
regression models were then used to evaluate 
the effects of the main variables, i.e. time and 
dosage of methadone. Stata software was used 
to analyze these models and random effect was 
employed to counteract the effects of repeated 
testing. For data analysis, logistic regression 
model with random data patterns was utilized. 
 
Results 
Of the 94 participants, 92 (97.9%) were men and 
two were women. The mean age of patients and 
the mean daily dosage of administered 
methadone were 40.9 years (range: 21-62 years) 
and 19.4 cc (range: 1-64 cc), respectively. Liver 
enzymes were found to be normal prior to the 
24th month. After that however, half of the 
patients exhibited elevated ALP levels. 
Abnormal AST and ALT levels were also 
detected in 4 (4.3%) and 3 (3.2%) patients, 
respectively (Table 1).  
As apparent from table 2, patients with 
abnormal ALP levels had a mean age and a 
mean methadone dosage of 39.9 years and 19.5 
cc, respectively. The corresponding values 
were found to be 54.3 years and 16 cc in 
patients with abnormal AST levels and 50.3 
years and 15 cc in patients with elevated ALT 
levels. Abnormal liver enzyme levels were not 
found to be significantly associated with age 
or methadone dosage.  
Patients were classified as younger than or 
equal to 40 years old and over 40 years of age. 
Of the patients with abnormal ALP levels, 26 
were below 40 years old and 20 patients aged 
over 40. Of the total 92 patients, 46 patients were 
found to have abnormal ALP levels in month 24. 
At the final measurement, 50 patients aged ≤ 40 
years old and 43 patients aged > 40 years of age. 
One patient younger than 40 years had missing 
data (ALP level was not measured at the 24th 
month). Therefore, out of 92 patients with 
complete data, 46 patients, all of whom were 
male, exhibited positive results in month 24.
 
Table 1. Frequency and 95% confidence interval (CI) of positive samples for alkaline phosphatase (ALP), alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) 
 ALT AST ALP 
 Percent (95% CI) Positive Number 
Percent 
(95% CI) Positive Number 
Percent 
(95% CI) Positive Number 
Baseline - 0 85 - 0 85 - 0 86 
6th month - 0 51 - 0 51 - 0 51 
12th month - 0 55 - 0 55 - 0 53 
18th month - 0 54 - 0 54 - 0 54 
24th month 3.2  (0-6.8) 3 93 
4.3  
(0.36-8.2) 4 93 
50.0  
(40.0-60.0) 46 92 
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; CI: Confidence intervals 
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Table 2. Patients' age and methadone dose based on the defective enzyme 
Enzyme (u/l) Index Range Mean ± SD 
ALP 
Normal (25-112) 
 
Age (years) 21-59 39.9 ± 9.5 
Dose (cc) 4-45 19.5 ± 8.5 
Abnormal 
 
Age (years) 21-62 41.2 ± 9.1 
Dose (cc) 1-64 18.9 ± 11.3 
AST 
Normal (10-44) 
 
Age (years) 53-56 54.3 ± 0.5 
Dose (cc) 13-21 16.0 ± 4.4 
Abnormal 
 
Age (years) 21-62 40.1 ± 9.1 
Dose (cc) 1-64 19.0 ± 10.9 
ALT 
Normal (10-31) 
 
Age (years) 38-56 50.3 ± 8.3 
Dose (cc) 12-21 15.0 ± 4.1 
Abnormal Age (years) 21-62 40.8 ± 9.2 Dose (cc) 1-64 19.0 ± 11.0 
ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase  
 
Four male patients (4.3%) (one younger than 
40 years old) were found to have abnormal ALT 
levels in month 24. The numbers of patients with 
complete ALT test results at baseline and after 6, 
12, 18, and 24 months were 86, 51, 55, 54, and 93, 
respectively. The corresponding numbers of 
patients with complete AST test results were 85, 
51, 55, 54, and 93. Only three patients (3.2%), all 
of whom aged over 40, exhibited abnormal AST 
levels in month 24. In patients with abnormal 
ALT, three patients received less than 20 cc of 
methadone while one subject received over 20 
cc. On the other hand, two and one patients with 
abnormal AST levels received < 20 cc and > 20 cc 
of methadone, respectively. 
 
Discussion 
In the present study, half of the patients 
exhibited abnormal ALP levels at the end of 
the study (month 24). Abnormal AST and ALT 
levels were found in 4.3% and 3.2% of the 
patients, respectively. Despite the small 
sample size, the observed levels may indicate 
the cholestatic pattern of liver injury 
(obstructive) due to methadone. This pattern is 
mainly caused by drugs suppressing bile 
secretion from the liver. Despite the higher 
prevalence of hepatitis B and C in addicts and 
the subsequent liver enzyme elevations, lack 
of ALT and AST elevations in most of our 
cases is noteworthy.  
Similarly, Tashakori et al.11 evaluated 98 
addicts (71% heroin-dependent, 7 subjects HIV 
positive) on methadone maintenance treatment 
and found liver function test results to remain 
in the normal range during the year following 
treatment. However, liver enzyme levels of HIV 
positive patients elevated shortly after 
methadone treatment and remained moderate 
afterwards.11 
In a three-year long study, Kreek et al. 
assessed methadone hepatotoxicity in 214 
patients (with or without hepatic disease) on 
high dose methadone maintenance treatment 
(80-120 mg daily). None of the 129 patients who 
completed the study showed signs of 
hepatotoxicity by methadone. Among these, 
23% had a history of hepatitis and 25% were 
moderate to heavy alcohol consumers. Liver 
test abnormalities were reported in 57% of the 
subjects at the time of admission. Three years 
after the initiation of treatment, 51% of 
abnormalities were associated with hepatitis or 
alcohol consumption.9 Although we did not 
consider existing liver and heart conditions 
and the consumption of alcohol or other 
drugs, the mentioned studies strongly confirm 
our findings. 
ALP is a non-specific enzyme which is 
elevated in a number of disorders such as various 
bone, heart, and kidney diseases and also in 
cholestatic liver disorders and liver infiltration. 
Limitations of the present study included small 
sample size, the retrospective nature of the trial, 
and the inability to include other liver tests and 
tests related to viral hepatitis. Further prospective 
studies with larger sample size encompassing 
various tests for evaluating liver function, viral 
hepatitis, alcohol consumption and other drugs 
(affecting liver function or causing cholestatic 
liver) are required to gain a more accurate insight 
into the effects of methadone on liver. However, 
despite various limitations, this study indicated 
significant effects of methadone on patients' ALP 
levels. Absence of obvious effects on liver 
transaminases (ALT, AST) may suggest 
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cholestatic (obstructive) liver damage by 
methadone. 
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  ﭼﻜﻴﺪه
 اﭘﻴﻮﻳﻴﺪﻫﺎ ﺗﺮك ﻣﺪت ﻃﻮﻻﻧﻲ ﺑﻪ ﺧﺼﻮص و ﻣﺪت ﻛﻮﺗﺎه درﻣﺎن در اﺳﺘﻔﺎده ﻣﻮرد داروي ﺗﺮﻳﻦ ﺷﺎﻳﻊ ﻣﺘﺎدون ﺣﺎﺿﺮ ﺣﺎل در: ﻣﻘﺪﻣﻪ
 يﺑﺮا آﻧﺎن در ﻫﻤﻜﺎري ﻛﺒﺪ ﺑﻪ وﻳﮋه ﻫﺎ ارﮔﺎن ﻋﻤﻠﻜﺮد ﺑﺮ ﻣﺘﺎدون ﻣﻨﻔﻲ اﺛﺮات ﺧﺼﻮص در ﺑﻴﻤﺎران ﺑﺎورﻫﺎي ﻫﻤﭽﻨﻴﻦ. ﺑﺎﺷﺪ ﻣﻲ
 ﺑﺎ ﻧﮕﻬﺪارﻧﺪه درﻣﺎن ﺗﺤﺖ ﺑﻴﻤﺎران در ﻛﺒﺪي ﻫﺎي آﻧﺰﻳﻢ ﺑﺮ ﻣﺘﺎدون ﺗﺄﺛﻴﺮ ﺑﺮرﺳﻲ ﻫﺪف، ﺑﺎ ﻣﻄﺎﻟﻌﻪ اﻳﻦ .اﺳﺖ ﺗﺄﺛﻴﺮﮔﺬار دارو ﻣﺼﺮف
  .ﺷﺪ اﻧﺠﺎم ﻣﺘﺎدون
 TMM ﻛﻠﻴﻨﻴﻚ در ﻣﺘﺎدون ﺑﺎ ﻧﮕﻬﺪارﻧﺪه درﻣﺎن ﺗﺤﺖ ﺑﻴﻤﺎر 49 ﺑﺮ روي ﻧﮕﺮ ﮔﺬﺷﺘﻪ ﺻﻮرت ﺑﻪ ﻣﻄﺎﻟﻌﻪ ﺣﺎﺿﺮ :ﻫﺎ روش
 ﻣﺎه 6 ﻫﺮ ﺑﻴﻤﺎران ﻛﺒﺪي ﻫﺎي آﻧﺰﻳﻢ. ﺷﺪ اﻧﺠﺎم ﻛﺮﻣﺎن ﺑﻬﺸﺘﻲ ﺷﻬﻴﺪ ﺑﻴﻤﺎرﺳﺘﺎن( tnemtaert ecnanetniam enodahteM)
 و ﺳﻦ و ﻛﺒﺪي ﻫﺎي آﻧﺰﻳﻢ ﺳﻄﻮح ارﺗﺒﺎط ﺑﺮ اﺳﺎس ﻧﺘﺎﻳﺞ و ﺷﺪ ﺛﺒﺖ 42 ﻣﺎه ﭘﺎﻳﺎن ﺗﺎ TMM ﻛﻠﻴﻨﻴﻚ ﺑﻪ ورود اﺑﺘﺪاي از ﻳﻚ ﺑﺎر
 ﻫﺎي داده ﻃﺮح ﺑﺎ noisserger citsigoL ﻣﺪل از ﻫﺎ داده ﺗﺤﻠﻴﻞ و ﺗﺠﺰﻳﻪ ﺟﻬﺖ. ﺷﺪ اﺳﺘﺨﺮاج ﻣﺼﺮﻓﻲ ﻣﺘﺎدون دوز و ﺟﻨﺲ
  .ﺷﺪ اﺳﺘﻔﺎده ﺗﺼﺎدﻓﻲ
 3/2) ﻧﻔﺮ 3در ( esarefsnart etatrapsA) TSAو ( درﺻﺪ 4/3) ﻧﻔﺮ 4در ( esarefsnart eninalA) TLA ﻣﻘﺪار :ﻫﺎ ﻳﺎﻓﺘﻪ
( esatahpsohp enilaklA) PLA ﺳﻄﻮح 42 ﻣﺎه در( درﺻﺪ 05) ﻧﻔﺮ 64 اﻣﺎ ﺑﻮد، ﻃﺒﻴﻌﻲ ﺣﺪ از ﺑﺎﻻﺗﺮ( آﺧﺮ) 42 ﻣﺎه در( درﺻﺪ
 ﻃﺒﻴﻌﻲ، ﻏﻴﺮ PLA اﻓﺮاد ﺑﺎ ﺳﻨﻲ ﺎﻧﮕﻴﻦﻣﻴ)ﺑﻮدﻧﺪ  ﺳﺎل 04 ﺑﺎﻻي ﻧﻔﺮ 02 و ﺳﺎل 04زﻳﺮ  ﻧﻔﺮ 62 ﺗﻌﺪاد، اﻳﻦ از ؛داﺷﺘﻨﺪ ﻃﺒﻴﻌﻲ ﻏﻴﺮ
  .ﺑﻮد (enodahtem fo cc hcaE=  5 gm) 91/5cc ﻫﺎ  در آن دوز ﻣﺼﺮﻓﻲ ﻣﺘﺎدون ﻣﻴﺎﻧﮕﻴﻦ و ﺳﺎل ﺑﻮد 93/9
 ﻛﻠﺴﺘﺎﺗﻴﻚ آﺳﻴﺐ اﻟﮕﻮي اﺣﺘﻤﺎﻟﻲ ﻧﺸﺎﻧﻪ ﻛﻪ ﺑﺎﺷﺪ ﻣﻲ PLAﺑﺮ  ﻣﺘﺎدون ﭼﺸﻤﮕﻴﺮ ﺗﺄﺛﻴﺮ از ﺣﺎﻛﻲ ﺣﺎﺿﺮ ﻣﻄﺎﻟﻌﻪ ﻧﺘﺎﻳﺞ :ﮔﻴﺮي ﻧﺘﻴﺠﻪ
و  ﺑﻴﺸﺘﺮ ﻧﻤﻮﻧﻪ ﺣﺠﻢ و ﺑﺎ ﻧﮕﺮ آﻳﻨﺪه ﺑﻪ ﺻﻮرت ﺑﻴﺸﺘﺮ ﻣﻄﺎﻟﻌﺎت، ﻣﻄﺎﻟﻌﻪ اﻳﻦ ﻧﺘﺎﻳﺞ ﺗﺄﻳﻴﺪ ﺑﺮاي. اﺳﺖ ﻛﺒﺪ ﺑﺮ ﻣﺘﺎدون( اﻧﺴﺪادي)
  .ﺷﻮد ﻣﻲ ﺗﻮﺻﻴﻪ ﻗﺒﻠﻲ ﻛﺒﺪي ﻫﺎي ﺑﻴﻤﺎري و ﻣﺼﺮﻓﻲ داروﻫﺎي ﺳﺎﻳﺮ ﮔﺮﻓﺘﻦ ﻧﻈﺮ در ﻫﻤﭽﻨﻴﻦ
  PLA، TSA، TLAﻣﺘﺎدون، ﺳﻮء ﻣﺼﺮف ﻣﻮاد، ﻛﺒﺪ،  :واژﮔﺎن ﻛﻠﻴﺪي
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